Business Jan 2, 2019
China's generic drug makers struggle to survive bulk-buy policy onslaught
Even after a plunge last month that wiped $46 billion off Chinese health-care stocks, domestic drug makers may be far from their floor as a Beijing-led policy shift gathers pace. China's plan to drive down generic drug prices through a centralized bulk procurement program is ...